Literature DB >> 22442003

Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter).

Yo-Ichi Yamashita1, Kazuki Takeishi, Eiji Tsuijita, Shouhei Yoshiya, Kazutoyo Morita, Hiroto Kayashima, Tomohiro Iguchi, Akinobu Taketomi, Ken Shirabe, Yoshihiko Maehara.   

Abstract

BACKGROUND: The effects of preoperative lipiodolization (LPD) for large hepatocellular carcinoma (HCC) are controversial.
METHODS: A retrospective review was undertaken for 137 patients with initial solitary resectable HCC ≥ 5 cm who underwent hepatic resection between 1995 and 2008. Forty-two patients underwent preoperative LPD, and clinical data and prognosis were compared to those of patients without preoperative LPD (n=95).
RESULTS: Surgical results of the LPD group, such as surgical time, surgical blood loss, and the mortality and morbidity rate were statistically equal to those of the nonLPD group. The disease-free and overall survival of the LPD group were significantly better than those of the nonLPD group, and early tumor recurrence within 1-year of the LPD group was significantly lower than that of the nonLPD group. According to the multivariate analysis, the absence of preoperative LPD was an independent poor prognostic factor of patients with hepatic resection for HCC ≥ 5 cm.
CONCLUSION: Preoperative LPD suppressed early tumor recurrence and improved patient survival after hepatic resection for HCC ≥ 5 cm.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22442003     DOI: 10.1002/jso.23098

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.

Authors:  Chao Li; Ming-Da Wang; Lun Lu; Han Wu; Jiong-Jie Yu; Wan-Guang Zhang; Timothy M Pawlik; Yao-Ming Zhang; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Hao Xing; Zhen-Li Li; Wan Yee Lau; Meng-Chao Wu; Feng Shen; Tian Yang
Journal:  Hepatol Int       Date:  2019-09-05       Impact factor: 6.047

2.  Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Qunfang Zhou; Fei Tuo; Ruixia Li; Xiaohui Wang; Juncheng Wang; Zhimei Huang; Minshan Chen; Jinhua Huang
Journal:  Front Oncol       Date:  2020-11-04       Impact factor: 6.244

3.  Guiding Value of Circulating Tumor Cells for Preoperative Transcatheter Arterial Embolization in Solitary Large Hepatocellular Carcinoma: A Single-Center Retrospective Clinical Study.

Authors:  Qiao Zhang; Feng Xia; Ali Mo; Weiming He; Jiazhen Chen; Weiqiao Zhang; Weiqiang Chen
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

4.  Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma.

Authors:  Lei Jianyong; Zhong Jinjing; Yan Lunan; Zhu Jingqiang; Wang Wentao; Zeng Yong; Li Bo; Wen Tianfu; Yang Jiaying
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

5.  Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence.

Authors:  Ye Xin Koh; Hwee Leong Tan; Weng Kit Lye; Juinn Huar Kam; Adrian Kah Heng Chiow; Siong San Tan; Su Pin Choo; Alexander Yaw Fui Chung; Brian Kim Poh Goh
Journal:  World J Hepatol       Date:  2018-06-27

Review 6.  Intraarterial Therapies for the Management of Hepatocellular Carcinoma.

Authors:  Tushar Garg; Apurva Shrigiriwar; Peiman Habibollahi; Mircea Cristescu; Robert P Liddell; Julius Chapiro; Peter Inglis; Juan C Camacho; Nariman Nezami
Journal:  Cancers (Basel)       Date:  2022-07-10       Impact factor: 6.575

7.  Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma.

Authors:  Yanming Zhou; Xiaofeng Zhang; Lupeng Wu; Feng Ye; Xu Su; Lehua Shi; Bin Li
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.